Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic
Examines modality of treatment delivery for patients with opioid use disorder (OUD) and how various modalities are associated with 90-day patient retention. Analyzes 17,182 Veterans Health Administration (VHA) patients who received buprenorphine for OUD treatment from March 2020 to March 2021 by video, telephone, in-person care, or a combination of the modalities. Includes data broken down by age, sex, race/ethnicity, VHA eligibility, housing status, substance use, mental health, comorbidities, and rurality, including urban, large rural, small/isolated rural, and unknown location.
Madeline C. Frost, Lan Zhang, H. Myra Kim, Lewei (Allison) Lin
JAMA Network Open, 5(10), e2236298
Illicit drug use · Infectious diseases · Pharmacy and prescription drugs · Prescription drug misuse · Rural-urban differences · Statistics and data · Telehealth · Veterans